RB1 mutation	Urothelial Cancer	RB1 mutation	Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RB1 mutation	Bladder Cancer	RB1 mutation	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RB1 mutation	Small Cell Lung Cancer	RB1 mutation	Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
RB1 mutation	Prostate Cancer	RB1 mutation	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
RB1 mutation	Prostate Cancer	RB1 mutation	Prostate Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
RB1 mutation	Triple Negative Breast Cancer	RB1 mutation	Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: C3 – Early Trials carboplatin + docetaxel Sensitive : C3	carboplatin + docetaxel Sensitive: C3 – Early Trials carboplatin + docetaxel Sensitive : C3
RB1 mutation	Ovarian Cancer	RB1 mutation	Ovarian Cancer	carboplatin + paclitaxel Resistant: C3 – Early Trials carboplatin + paclitaxel Resistant : C3	carboplatin + paclitaxel Resistant: C3 – Early Trials carboplatin + paclitaxel Resistant : C3
RB1 mutation	Non Small Cell Lung Cancer	RB1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
RB1 mutation	Prostate Cancer	RB1 mutation	Prostate Cancer	cyclophosphamide Sensitive: C4 – Case Studies cyclophosphamide Sensitive : C4	cyclophosphamide Sensitive: C4 – Case Studies cyclophosphamide Sensitive : C4
RB1 mutation	Meningioma	RB1 mutation	Meningioma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
RB1 mutation	Ovarian Cancer	RB1 mutation	Ovarian Cancer	abemaciclib Resistant: D – Preclinical abemaciclib Resistant : D	abemaciclib Resistant: D – Preclinical abemaciclib Resistant : D
RB1 mutation	Small Cell Lung Cancer	RB1 mutation	Small Cell Lung Cancer	nivolumab + ipilimumab Resistant: D – Preclinical nivolumab + ipilimumab Resistant : D	nivolumab + ipilimumab Resistant: D – Preclinical nivolumab + ipilimumab Resistant : D

RB1 mutation

Associations